

DEAH-box helicase 37 (*DHX37*) defects are a novel molecular etiology of 46,XY gonadal dysgenesis spectrum

Thatiana E. da Silva,¹ Nathalia L. Gomes,¹ Antonio M. Lerario,^{2,3} Catherine E. Keegan,^{4,5} Mirian Y. Nishi,¹ Filomena M. Carvalho,⁶ Eric Vilain,⁷ Hayk Barseghyan,⁷ Alejandro Martinez-Aguayo,⁸ María V. Forclaz,⁹ Regina Papazian⁹, Luciani R. Carvalho,¹ Elaine M. F. Costa,¹ Berenice B. Mendonca,^{1,2} Sorahia Domenice,¹

¹Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular (LIM/42) da Disciplina de Endocrinologia e Metabologia do Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 05403900

² Laboratório de Sequenciamento em Larga Escala (SELA), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

³ Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

⁴ Department of Pediatric Genetics, University of Michigan Medical School, Ann Arbor, MI, USA

⁵ Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA

⁶ Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 05403900

⁷ Center for Genetic Medicine Research, Children's National Health System, Children's Research Institute, Children's National Medical Center, Washington, DC, USA

⁸ Division de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 8331150

⁹ Servicio de Pediatría, Hospital Nacional Prof. Dr. A. Posadas, Buenos Aires, Argentina, 1684

First authors da Silva, T E and Gomes NL and last authors Mendonca BB and Domenice S contributed equally to this article.

*Corresponding authors: Berenice B Mendonca and Sorahia Domenice

Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Disciplina de Endocrinologia e Metabologia.

Av. Dr. Enéas de Carvalho Aguiar, 155, 2º andar, bloco 6

CEP: 05403-900, São Paulo, Brasil.

Email: beremen@usp.br.

Phone number: 55 11 2661-7564; 55 11 2661-7512

E-mail address: silva.thatiana@yahoo.com.br;

nathalia.endocrino@gmail.com; beremen@usp.br;

sorahiad@gmail.com;

Short title: *DHX37* defects in patients with 46,XY GD spectrum

ABSTRACT

46, XY gonadal dysgenesis is a heterogeneous disorder of sex development (DSD) that features abnormal gonadal development and varying degrees of undervirilization of the external genitalia, ranging from micropenis to female-like genitalia. Embryonic testicular regression syndrome (ETRS; MIM: 273250) is considered part of the clinical spectrum of 46,XY gonadal dysgenesis. Most ETRS patients present micropenis or atypical genitalia associated with a complete absence of gonadal tissue in one or both sides. In most patients with gonadal dysgenesis, the genetic diagnosis is unclear. We performed whole exome sequencing in ETRS patients and identified a rare variant, the p.Arg308Gln, in DEAH (Asp-Glu-Ala-His) box polypeptide 37 (*DHX37*) in 5 affected individuals from three unrelated families. We expanded the analysis of *DHX37* coding region to additional 71 patients with 46,XY gonadal dysgenesis and identified the p.Arg308Gln and three other *DHX37* missense variants (p.Arg151Trp, p.Thr304Met and p.Arg674Trp) in 11 affected members from eight distinct families (8 patients with ETRS, two with partial gonadal dysgenesis and one 46,XY DSD female patient previously gonadectomized). The p.Arg308Gln and p.Arg674Trp recurrent variants were identified in six and three families, respectively. Segregation analysis revealed sex-limited autosomal dominant inheritance in 4 families, autosomal dominant with incomplete penetrance in one family and autosomal recessive in another family. Immunohistochemical analysis of normal testes revealed that *DHX37* is expressed in germ cells at different stages of maturation.

This study demonstrates an expressive frequency of rare predicted to be deleterious *DHX37* variants in 46,XY gonadal dysgenesis group, particularly those individuals exhibiting the ETRS phenotype (25% and 50%, respectively).

Our findings indicate that *DHX37* is a new player in the complex cascade of male gonadal differentiation and maintenance, thus establishing a novel and frequent molecular etiology for 46,XY gonadal dysgenesis spectrum, mainly for embryonic testicular regression syndrome.

Introduction

46,XY gonadal dysgenesis is a heterogeneous disorder of sex development (DSD) that features abnormal gonadal development and varying degrees of undervirilization of the external genitalia, ranging from micropenis to female-like genitalia. The gonads from these patients present a wide array/spectrum of histological abnormalities, ranging from disorganized seminiferous tubules and the presence of an ovarian-like stroma, to complete absence of testicular tissue. Müllerian structures may be partially or fully developed in these patients¹. Embryonic testicular regression syndrome (ETRS; MIM: 273250) is considered part of the clinical spectrum of 46,XY gonadal dysgenesis. Most ETRS patients present micropenis or atypical genitalia associated with a complete absence of gonadal tissue in one or both sides. The presence of micropenis suggests that functioning testes were present during early fetal development, but disappeared before birth^{2,3}.

Several genetic defects have been described in sporadic and familial forms of 46,XY gonadal dysgenesis, but the genetic etiology of most patients remains unknown⁴⁻⁸.

Here, we used next generation-sequencing based methods, including whole-exome sequencing and targeted gene panels, to investigate the underlying genetic etiology in a large cohort of 46,XY patients with gonadal dysgenesis of unknown cause. We identified recurrent rare variants in DEAH (Asp-Glu-Ala-His) box polypeptide 37 (*DHX37*) in several affected individuals from distinct families, establishing a novel genetic cause for 46,XY gonadal dysgenesis spectrum.

Ethics

This study was approved by the Ethics Committee of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, the Institutional Review Board of the University of Michigan Medical School, the Hospital de Garrahan Escuela de Medicina, Pontificia Universidad Católica de Chile, and the Hospital Nacional Prof. Dr. A. Posadas, Buenos Aires, Argentina. Written informed consent was obtained from all patients, their parents or legal guardians.

Subjects and Methods

Four children from two Brazilian families (Family 1 and 2) and one Chinese-American child with ETRS were firstly studied by whole-exome sequencing. Two additional families with ETRS (one from Chile, the other from Argentina) (Table 1 and 2) and 71 Brazilian patients with sporadic 46,XY DSD (39 patients with partial and complete 46,XY gonadal dysgenesis (atypical genitalia, presence of Mullerian derivatives and/or at least one dysgenetic gonad or absence of gonadal tissue) and thirty-two 46,XY DSD patients with unknown etiology (molecular defects in LHCG and androgen receptor genes and *5ARD2* gene were ruled out by Sanger method as well as testosterone synthesis defects by hormonal evaluation) or due to previously gonadectomy. All patients have a normal GTG-banded metaphases 46,XY karyotype.

Molecular Analysis

Molecular studies were performed by targeted massively parallel sequencing or Sanger sequencing. Details of DNA extraction, Sanger and massive parallel sequencing, variant filtering and immunohistochemical staining analysis are available in the Supplementary Data.

Molecular analysis was performed on genomic DNA obtained from peripheral leukocytes. The identified allelic variants in massive parallel sequencing were subsequently confirmed by Sanger

method as well as segregation analysis of the candidate variants. Allelic variants were considered to be deleterious when they were predicted to be pathogenic by at least three of the following *in silico* algorithms (SIFT, PolyPhen2, Mutation Taster, Mutation Assessor, FATHMM, LRT, LR score, and radial SVM) and by the conservation scores (GERP++, SiPhy, PhyloP, CADD score). In order to select disease-causing variants, we excluded those with a minor allele frequency (> 0.5%) in publicly available population databases (gnomAD, 1000 Genomes, dbSNP, ExAC, ESP6500, ABraOM-Brazilian Genomic Variants) and in 548 Brazilian in-house controls.

Protein interaction networks (National Center for Biotechnology Information [NCBI], Biogrid, and String databases) were used to evaluate interaction among proteins which are co-expressed with DHX37 in testicular cells. Using protein interactions we constructed an hypothetical cascade of testicular differentiation including DHX37.

Histological analysis

One single pathologist (FMC) reviewed the histology of the gonadal tissue samples from all Brazilian patients.

Immunohistochemical staining study

Eight formalin-fixed paraffin-embedded testicular necropsy samples from 46,XY individuals with different chronological ages (27 and 33 weeks gestational age, 1, 53, and 180 days of age, 13, 23 and 53 years of age) were collected and used for DHX37 expression analysis by immunohistochemistry.

Statistical analysis

To provide additional genetic evidence of the association of *DHX37* with gonadal dysgenesis phenotype, we performed aggregate variant analyses comparing allele frequencies between our cohort of 46,XY DSD patients and public databases (gnomAD and ABraOM). In public

databases, we selected variants with similar characteristics of the *DHX37* variants observed in our cohort: rare nonsynonymous variants (minor allele frequency of 0.01) located in the two highly conserved protein domains (ATP-binding and Helicase C-terminal domains) that are predicted to be pathogenic by at least four *in silico* tools (PROVEAN, SIFT, PolyPhen-2, and Mutation Assessor). Allele frequency differences between groups were analyzed by χ^2 test, and statistical significance was set at $P < 0.05$. Statistical analyses were performed by using the SIGMAstat statistical software package (Windows version 4.0; SPSS Inc., San Rafael, CA).

Results

Exome sequencing nominated DHX37 as a candidate gene in three unrelated families.

The exome sequencing data identified the single missense *DHX37* variant, c.923C>T [p.Arg308Gln]; GenBank: NM_032656.3, in three unrelated families with 46,XY gonadal dysgenesis (Figure 1). *DHX37* is a member of the large DEAH family of proteins and encodes an RNA helicase^{11,12}. The *DHX37* protein is comprised by 1157 amino acids and four main domains, including the conserved motifs of the helicase core region; the Helicase ATP-binding (position 262-429) and the Helicase superfamily c-terminal domain (position 585-674), in addition to the helicase associated domain (position 768-859) and the oligonucleotide/oligosaccharide-binding-fold (position 894-1011) (Figure 2). The p.Arg308Gln variant is predicted to be pathogenic by six *in-silico* prediction sites (Table S2) and is not present in genomic population databases, except in the gnomAD database, where this variant was found at a very low allele frequency (0.00003) (Table S3-S4). The p.Arg308Gln variant was not identified in Brazilian population: in 548 individuals by Sanger sequencing, in 308 by in-house exome and in 609 healthy Brazilian subjects from ABraOm database. Finally, our phasing analysis ruled out a founder effect in Brazilian families 1 and 2. To identify other possible

pathogenic variants on *DHX37*, we further extended our study to include 81 patients with variable phenotypes of 46, XY gonadal dysgenesis. We studied the entire coding sequence of *DHX37* either by massive parallel sequencing (WES or DSD targeted panel) or Sanger sequencing (Table S1). Three other novel variants, the c.451G>A (p.Arg151Trp), the c.911C>T (p.Thr304Met) and the c.2020G>A (p.Arg674Trp) were identified in four distinct families: (Table 1 and 2, Figure 1). All were in heterozygous state, except the p.Arg151Trp variant.

The homozygous p.Arg151Trp was identified in one sporadic ETRS patient. The heterozygous p.Arg308Gln variant was identified in three Brazilian patients with sporadic ETRS. The p.Arg674Trp variant was identified in the two Chilean brothers with ETRS and in the three affected members of one Argentinian family (two brothers with ETRS, their uncle with partial GD) and in one Brazilian sporadic partial GD patient. The heterozygous p.Thr304Met was found in a Brazilian patient, who underwent previous gonadectomy (Tables 1 and 2, Figure 1).

The p.Thr304Met was located inside *DHX37* Helicase ATP-binding (position 262-429) and was classified as deleterious by six *in-silico* prediction sites (Figure 2, Table S2). The p.Thr304Met was not found in all searched population databases (Figure 2; Tables S3-S4).

The p.Arg674Trp variant was located in the Motif VI (position 667-674), inside the Helicase superfamily c-terminal domain, and was classified as deleterious by six *in silico* prediction tools (Table S2) and was not identified in all searched population databases (Figure 2; Table S3-S4).

The p.Arg151Trp (dbSNP: rs577400960) variant was located at the beginning of the protein sequence, outside the Helicase ATP-binding, and was classified as possibly deleterious by four *in silico* prediction tools (Figure 2; Table S2). It was found in heterozygous state in the 1000 Genome and in Brazilian controls with allele frequencies of 0.02% (1/5007). It was not identified in the ABraOM-Brazilian Genomic Variants and Brazilian in-house controls (Table S3 -S4).

Frequency of the *DHX37* variants in our 46,XY DSD cohort

The allele frequency of rare *DHX37* variants predicted to be deleterious found in our whole cohort of 46,XY DSD patients (10%) was expressively higher than that observed in individuals from gnomAD (568/141456 individuals [0.004%; $p < 0.001$]) and from the Brazilian cohort (1/609 individuals [0.002%; $p < 0.001$]). Our study demonstrated an expressive frequency of rare predicted to be deleterious *DHX37* variants in 46,XY gonadal dysgenesis group, particularly those individuals exhibiting the ETRS phenotype (25% and 50%, respectively).

Segregation analysis revealed different inheritance patterns

Segregation analysis of the *DHX37* variants in seven families displayed a sex-limited autosomal dominant pattern in three families (F2, F3, F4). In the Family 1, the presence of the p.Arg308Gln variant in the asymptomatic father suggests an autosomal dominant pattern of inheritance with incomplete penetrance. An autosomal recessive inheritance was identified in one consanguineous family (F7) (Figure 1). In two sporadic cases (F5:II-1 and F7:II-1) the confirmed paternity displayed a *de novo* status of the p.Arg308Gln *DHX37* variant (Figure 1).

Absence of founder effect of *DHX37* p.Arg308Gln variant

The comparative analysis of polymorphic markers located around the p.Arg308Gln variant in families 1 and 2 evaluated in exome data excluded the occurrence of founder effect.

***DHX37* protein identified in different stages of germ cells maturation**

To gain further insights on the role of *DHX37* in testicular development, we studied its expression in testes from newborn children and from adults by immunohistochemistry technique. *DHX37* expression analysis in newborns was found exclusively in spermatogonia and it was characterized by a regular perinuclear halo pattern. The same pattern is also observed in spermatogonia of adult testis. A progressive condensation of protein around the nucleus was

observed as cells changed from spermatocyte stage 1 to 2, generating a localized paranuclear pattern. A punctate perinuclear pattern of expression was observed in spermatids, but no staining was observed in spermatozoa (Figure 3).

Discussion

The present study analyzed a large cohort of 46,XY DSD patients without defined molecular diagnosis, most of them with gonadal dysgenesis phenotype (63%). Pathogenic allelic variants in the *DHX37* was identified in 16 affected members of 11 families. Deleterious variants are recurrent in familial and sporadic cases of 46,XY GD patients from different ethnicities.

Three variants identified in the present study are located in two highly conserved domains, the Helicase ATP-binding, which is a region associated with RNA-binding activity of the RNA helicases, and the Helicase superfamily c-terminal domain, associated with ATPase activity⁹. Rare and predicted deleterious *DHX37* variants are more frequently identified in our DSD cohort (14%) than in the public databases, emphasizing that the association of *DHX37* with 46,XY gonadal dysgenesis did not occur by chance ($p < 0.01$).

Since the discovery of *SRY* variants in patients with gonadal dysgenesis in 1990, several genes have been associated with molecular etiology of this disorder⁷. The nuclear receptor subfamily 5 group A member 1 (*NR5A1*) and *MAP3K1* variants are the most frequent causes of 46,XY gonadal dysgenesis¹⁰⁻¹².

In this study we found an expressive frequency (10%) of likely-pathogenic variants in *DHX37* in patients with 46,XY gonadal dysgenesis; considering only the ETRS phenotype (micropenis and absence of uni or bilateral testicular tissue) the frequency augmented to 50%.

The potential involvement of *DHX37* in the etiology of male gonadal development defects may be supposed by reports of patients with 12q24.31-33 deletions with syndromic features and

genital abnormalities^{13,14}.

DHX37 encodes an RNA helicase, which is involved in RNA-related process, including transcription, splicing, ribosome biogenesis^{15,16}, translation and degradation¹⁷. Mutations in DEAH Box RNA helicases members have been related to human neurogenic disorders. Disease-causing variants in the DEAH Box Polypeptide 30 (*DHX30* [MIM:616423]) gene, were previously described in syndromic patients with global developmental delay (GDD [MIM:166260]), intellectual disability (ID [MIM:614132]), severe speech impairment and gait abnormalities. Functional studies of the altered *DHX30* proteins, derived from conserved residue substitutions in the helicase nucleus domain, demonstrated that they affect protein folding or stability interfering with the RNA binding (mutations located in motif Ia) or with ATPase activity (mutations located in motif II and VI)⁹.

Homozygous *DHX37* mutations were previously identified by WES in affected members of two consanguineous families with neurogenetic disorders (developmental delay or intellectual disability) and brain malformations (severe microcephaly or cortical atrophy)¹⁸. Description of external genitalia or gonadal function of the patients with *DHX37* mutations and neurogenetic disorders was not available.

Neurogenetic disorder was noticed in only one Brazilian ETRS patient, in which the homozygous p.Arg151Trp variant was identified. She was born to a consanguineous Brazilian couple and at age of 4.25 years, she had developmental delay, poor speech and short stature. Unfortunately, her treatment was discontinued after surgery and no information about her was available. According to ACMG guidelines criteria, the p.Arg151Trp variant was classified as a variant of uncertain significance (VUS) (Table S4). This variant is located outside the helicase core region and it was found in heterozygous state in low frequency (0.02%) in the 1000

Genomes Database. Although these facts suggest that the heterozygous p.Arg151Trp variant has no significant phenotypic effect, we speculate a possible pathogenic role when it is in homozygous state, similarly to previous described for mild homozygous *NR5A1* mutations in 46,XY DSD patients^{19,20}.

The unique p.Thr304Met variant and the recurrent p.Arg308Gln variant were located in a region associated with RNA-binding activity of the RNA helicases⁹. The p.Arg308Gln variant was identified in 8 affected members of six families with ETRS but a founder effect for this variant was ruled out. Two patterns of inheritance of the p.Arg308Gln variant were revealed by segregation analysis: the sex-limited autosomal dominant mode found in 4 families and autosomal dominant with incomplete penetrance found in the Family 1. In the literature, different inheritance patterns had already been identified in 46,XY gonadal dysgenesis kindreds²¹, including the description of asymptomatic male members carriers of pathogenic variants of genes involved in the testicular determination as *SRY* and *NR5A1*^{19,22,23}.

The heterozygous p.Arg674Trp, identified in six affected members of three unrelated families with ETRS and partial GD phenotype, was transmitted as a sex-limited autosomal dominant mode. The Residue Arg674 is located in the Motif VI, other highly conserved position of the RNA helicases of Helicase associated with ATPase activity⁹.

DEAD-box proteins have been associated to the control cellular growth, proliferation and differentiation, and are known to be implicated in embryogenesis and spermatogenesis^{17,24}.

DExD/H-box RNA helicases regulate reproductive-related genes by modulating mRNA structures²⁵. RNA expression profiles of *DHX37* in human testicular cancer cells are higher than in other tissue (The Human Protein Atlas – Pathology), suggesting that the *DHX37* may be involved in the regulatory process of the testis cells proliferation.

Expression analysis of RNA helicase genes in channel catfish gonads demonstrated a sex-specific expression pattern. The *DEAD-box RNA helicase 5 (DDX5/p68* [MIM:180630]), *DEAD-box RNA helicase 21 (DDX21* [MIM:606357]) and *DEAH box Polypeptide 9 (DHX9* [MIM:603115]) were highly expressed during the critical period of male catfish gonadal differentiation indicating a role in male gonadal development²⁶.

In humans, the DHX37 protein is expressed in adults ovarian stroma and seminiferous duct cells (The Human Protein Atlas Database). In our study, the immunohistochemistry analysis of normal testicular tissue from stillborn, pubertal and adult males revealed that DHX37 was expressed during different stages of germ cell maturation. These findings suggest that DHX37 protein might have a role in the germ cell development. Although it is still unclear how germ cells contribute to the development and function of somatic cells in the testis, there is an elaborate paracrine cell-cell network transporting signaling molecules between germ cells and Sertoli cells²⁷. Indeed, *in vitro* studies have shown that there is a bidirectional trafficking between Sertoli and germ cells, and that each cell type regulates the function of the other²⁸⁻³¹.

Based on protein interaction networks we hypothesize that the role of DHX37 in male testicular development involves the regulation of the serine/threonine protein kinase encoded by *V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1* [MIM: 164730]). Our analysis suggests that DHX37 may interact with DEAH-box RNA helicase 15 (DHX15 [MIM: 603403]) and DDX5/p68, known regulators of *AKT1*^{32,33}. This serine-threonine kinase is expressed in germ cells and Sertoli cells and plays an important role in the proliferation, differentiation and maintenance of testicular tissue, including regulation of apoptosis in male germ cells³⁴. In addition, AKT1 also regulates the Mitogen-Activated Kinase 1 (MAP3K1)-RHOA/ROCK complex and, thus, the phosphorylation of p38/Mitogen-Activated Protein Kinase 14 (MAPK14

[MIM: 600289]), ERKs (Mitogen-Activated Protein Kinase, MAPK3 [MIM: 601795]; MAPK1 [MIM: 176948]), which are essential for SOX9 (MIM:608160) activation and testis determination (Figure 4)³⁵⁻³⁹. Further studies are necessary to clarify the precise role DHX37 plays in the signaling network that regulates testicular development and maintenance.

Our findings indicate that *DHX37* is a new player in the complex cascade of male gonadal differentiation and maintenance, thus establishing a novel and frequent molecular etiology for 46,XY gonadal dysgenesis spectrum, mainly for embryonic testicular regression syndrome.

Declaration of Interests

The authors declare no competing interests

Acknowledgments

This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Grant No. 305743/2011-2), the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Grants No. 05/04726-0, 07/512156, 10/51102-0, 2013/02162-8 and 2014/50137-5), and by the institutional fellowship grant from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/ PNPd). The authors are very grateful to Dr. Frederico Moraes Ferreira for his technical assistance with the *in silico* prediction analysis, and Dr. Beverly M. Yashar and Dr. John Park for medical care of patient F5:II-1.

References

1. Mendonca BB, Domenice S, Arnhold IJP, Costa EMF. 46,XY disorders of sex development (DSD). *Clin Endocrinol (Oxf)*. 2009;70(2):173-187. doi:10.1111/j.1365-2265.2008.03392.x.
2. Josso N, Briard ML. Embryonic testicular regression syndrome: Variable phenotypic expression in siblings. *J Pediatr*. 1980;97(2):200-204. doi:10.1016/S0022-3476(80)80474-4.
3. Marcantonio SM, Fechner PY, Migeon CJ, Perlman EJ, Berkovitz GD. Embryonic testicular regression sequence: A part of the clinical spectrum of 46,XY gonadal dysgenesis. *Am J Med Genet*. 1994;49(1):1-5. doi:10.1002/ajmg.1320490102.
4. Bashamboo A, McElreavey K. Gene mutations associated with anomalies of human gonad formation. *Sex Dev*. 2012;7(1-3):126-146. doi:10.1159/000342188.
5. Bashamboo A, Ledig S, Wieacker P, Achermann JC, Achermann J, McElreavey K. New technologies for the identification of novel genetic markers of disorders of sex development (DSD). *Sex Dev*. 2010;4(4-5):213-224. doi:10.1159/000314917.
6. Mazen I, Abdel-Hamid M, Mekkawy M, et al. Identification of *NR5A1* Mutations and Possible Digenic Inheritance in 46,XY Gonadal Dysgenesis. *Sex Dev*. 2016;10(3):147-151. doi:10.1159/000445983.
7. Bashamboo A, Brauner R, Bignon-Topalovic J, et al. Mutations in the FOG2/ZFPM2 gene are associated with anomalies of human testis determination. *Hum Mol Genet*. 2014;23(14):3657-3665. doi:10.1093/hmg/ddu074.
8. Werner R, Merz H, Birnbaum W, et al. 46,XY Gonadal Dysgenesis due to a Homozygous

- Mutation in Desert Hedgehog (DHH) Identified by Exome Sequencing. *J Clin Endocrinol Metab.* 2015;100(7):E1022-9. doi:10.1210/jc.2015-1314.
9. D. L, C. S, S. K, et al. De Novo Missense Mutations in DHX30 Impair Global Translation and Cause a Neurodevelopmental Disorder. *Am J Hum Genet.* 2017;101(5):716-724. doi:<http://dx.doi.org/10.1016/j.ajhg.2017.09.014>.
 10. Pearlman A, Loke J, Le Caignec C, et al. Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. *Am J Hum Genet.* 2010;87(6):898-904. doi:10.1016/j.ajhg.2010.11.003.
 11. Domenice S, Machado AZ, Ferreira FM, et al. Wide spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. *Birth Defects Res C Embryo Today.* 2016;108(4):309-320. doi:10.1002/bdrc.21145.
 12. Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. *Best Pract Res Clin Endocrinol Metab.* 2015;29(4):607-619. doi:10.1016/j.beem.2015.07.004.
 13. Sathya P, Tomkins DJ, Freeman V, Paes B, Nowaczyk MJ. De novo deletion 12q: report of a patient with 12q24.31q24.33 deletion. *Am J Med Genet.* 1999;84(2):116-119. <http://www.ncbi.nlm.nih.gov/pubmed/10323735>. Accessed May 20, 2017.
 14. Al-Zahrani J, Al-Dosari N, Abudheim N, et al. Chromosome 12q24.31-q24.33 deletion causes multiple dysmorphic features and developmental delay: First mosaic patient and overview of the phenotype related to 12q24qter defects. *Mol Cytogenet.* 2011;4:9. doi:10.1186/1755-8166-4-9.
 15. Bleichert F, Baserga SJ. The Long Unwinding Road of RNA Helicases. *Mol Cell.* 2007;27(3):339-352. doi:10.1016/j.molcel.2007.07.014.

16. Colley A, Beggs JD, Tollervey D, Lafontaine DL. Dhr1p, a putative DEAH-box RNA helicase, is associated with the box C+D snoRNP U3. *Mol Cell Biol.* 2000;20(19):7238-7246. <http://www.ncbi.nlm.nih.gov/pubmed/10982841>. Accessed July 17, 2017.
17. Jankowsky E, Gross CH, Shuman S, Pyle AM. Active Disruption of an RNA-Protein Interaction by a DExH/D RNA Helicase. *Science (80-)*. 2001;291(5501):121-125. doi:10.1126/science.291.5501.121.
18. Karaca E, Harel T, Pehlivan D, et al. Genes that Affect Brain Structure and Function Identified by Rare Variant Analyses of Mendelian Neurologic Disease. *Neuron*. 2015;88(3):499-513. doi:10.1016/j.neuron.2015.09.048.
19. Achermann JC, Ozisik G, Ito M, et al. Gonadal Determination and Adrenal Development Are Regulated by the Orphan Nuclear Receptor Steroidogenic Factor-1, in a Dose-Dependent Manner. *J Clin Endocrinol Metab.* 2002;87(4):1829-1833. doi:10.1210/jcem.87.4.8376.
20. Soardi FC, Coeli FB, Maciel-Guerra AT, Guerra-Júnior G, Palandi de Mello M. Complete XY gonadal dysgenesis due to p.D293N homozygous mutation in the NR5A1 gene: A case study. *J Appl Genet.* 2010;51(2):223-224. doi:10.1007/BF03195733.
21. Sarafoglou K, Ostrer H. Familial Sex Reversal: A Review. *J Clin Endocrinol Metab.* 2000;85(2):483-493. doi:10.1210/jcem.85.2.6418.
22. Assumpção J, Benedetti C, Maciel-Guerra A, et al. Novel mutations affecting SRY DNA-binding activity: the HMG box N65H associated with 46,XY pure gonadal dysgenesis and the familial non-HMG box R30I associated with variable phenotypes. *J Mol Med.* 2002;80(12):782-790. doi:10.1007/s00109-002-0376-9.

23. Philibert P, Polak M, Colmenares A, et al. Predominant Sertoli cell deficiency in a 46,XY disorders of sex development patient with a new NR5A1/SF-1 mutation transmitted by his unaffected father. *Fertil Steril*. 2011;95(5). doi:10.1016/j.fertnstert.2010.11.035.
24. de la Cruz J, Kressler D, Linder P, Faye G. Unwinding RNA in *Saccharomyces cerevisiae*: DEAD-box proteins and related families. *Trends Biochem Sci*. 1999;24(5):192-198. doi:10.1016/S0968-0004(99)01376-6.
25. Kotov a. a., Akulenko N V., Kibanov M V., Olenina L V. DEAD-Box RNA helicases in animal gametogenesis. *Mol Biol*. 2014;48(1):16-28. doi:10.1134/S0026893314010063.
26. Tian C, Tan S, Bao L, et al. DExD/H-box RNA helicase genes are differentially expressed between males and females during the critical period of male sex differentiation in channel catfish. *Comp Biochem Physiol Part D Genomics Proteomics*. 2017;22:109-119. doi:10.1016/J.CBD.2017.02.008.
27. Jégou B. The Sertoli-germ cell communication network in mammals. *Int Rev Cytol*. 1993;147:25-96. <http://www.ncbi.nlm.nih.gov/pubmed/8225836>. Accessed July 18, 2017.
28. SKINNER MK. Cell-Cell Interactions in the Testis*. *Endocr Rev*. 1991;12(1):45-77. doi:10.1210/edrv-12-1-45.
29. Cheng CY, Mruk DD. Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. *Physiol Rev*. 2002;82(4):825-874. doi:10.1152/physrev.00009.2002.
30. Rios-Rojas C, Bowles J, Koopman P. On the role of germ cells in mammalian gonad development: quiet passengers or back-seat drivers? 2015. <https://core.ac.uk/display/43369001>. Accessed July 18, 2017.
31. Svingen T, Koopman P. Building the mammalian testis: origins, differentiation, and

- assembly of the component cell populations. *Genes Dev.* 2013;27(22):2409-2426.
doi:10.1101/gad.228080.113.
32. Sandhu H, Lemaire L, Heinlein UAO. Male Germ Cell Extracts Contain Proteins Binding to the Conserved 3'-End of Mouse P68 RNA Helicase mRNA. *Biochem Biophys Res Commun.* 1995;214(2):632-638. doi:10.1006/bbrc.1995.2333.
33. Sarkar M, Khare V, Guturi KKN, Das N, Ghosh MK. The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis. *Oncogene.* 2015;34(47):5843-5856. doi:10.1038/onc.2015.42.
34. Hixon ML, Boekelheide K. Expression and Localization of Total Akt1 and Phosphorylated Akt1 in the Rat Seminiferous Epithelium. *J Androl.* 2003;24(6):891-898. doi:10.1002/j.1939-4640.2003.tb03141.x.
35. Zimmermann S, Moelling K. Phosphorylation and Regulation of Raf by Akt (Protein Kinase B). *Science (80-).* 1999;286(5445).
<http://science.sciencemag.org/content/286/5445/1741>. Accessed July 17, 2017.
36. Liao RS, Ma S, Miao L, Li R, Yin Y, Raj G V. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. *Transl Androl Urol.* 2013;2(3):187-196. doi:10.3978/j.issn.2223-4683.2013.09.07.
37. Shimada H, Rajagopalan LE. Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. *J Biol Chem.* 2010;285(17):12536-12542. doi:10.1074/jbc.M109.099630.
38. Bogani D, Siggers P, Brixey R, et al. Loss of mitogen-activated protein kinase kinase kinase 4 (MAP3K4) reveals a requirement for MAPK signalling in mouse sex determination. *PLoS Biol.* 2009;7(9). doi:10.1371/journal.pbio.1000196.
39. Loke J, Pearlman A, Radi O, et al. Mutations in MAP3K1 tilt the balance from

SOX9/FGF9 to WNT/??-catenin signaling. *Hum Mol Genet.* 2014;23(4):1073-1083.

doi:10.1093/hmg/ddt502.

Web Resources

1000 Genomes Project, <http://www.internationalgenome.org/>
ABraOM (<http://abraom.ib.usp.br/search.php>)
ANNOVAR (<http://annovar.openbioinformatics.org/en/latest/>)
biobambam2 suite (<https://launchpad.net/biobambam2>)
Beagle software (<http://faculty.washington.edu/browning/beagle/beagle.html>)
Biogrid (<https://thebiogrid.org/>)
CADD (<http://cadd.gs.washington.edu>)
dbSNP (<https://www.ncbi.nlm.nih.gov/SNP/>)
ESP6500 (<http://evs.gs.washington.edu/EVS/>)
ExAC Browser (<http://exac.broadinstitute.org/>)
FATHMM (<http://fathmm.biocompute.org.uk>)
FastQC, <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>
Freebayes (<https://github.com/ekg/freebayes>)
GATK, <https://software.broadinstitute.org/gatk/>
GenBank, <https://www.ncbi.nlm.nih.gov/genbank/>
GERP++ (<http://mendel.stanford.edu/SidowLab/downloads/gerp/>)
Human Protein Atlas (<https://www.proteinatlas.org/>)
IGV (<http://www.broadinstitute.org/igv/>)
Mutation Taster (<http://www.mutationtaster.org>)
Mutation Acessor (<http://mutationassessor.org/r3/>)
OMIM, <https://www.omim.org/>
PhyloP (<http://compgen.cshl.edu/phast/background.php>)
PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2/>)
SIFT (<http://sift.jcvi.org>)
SiPhy (http://portals.broadinstitute.org/genome_bio/siphy/index.html)
String (<https://string-db.org/>)

Table 1. Phenotype of familial 46,XY DSD patients with gonadal dysgenesis associated with heterozygous likely pathogenic *DHX37* variants

Origin		Brazilian		Brazilian		Chilean		Argentinian		
Parameters		F1:III-2	F1:III-3	F2:II-4	F2:III-1	F3:II-1	F3:II-2	F4:III-1	F4:III-2	F4:II-4
Subject		F1:III-2	F1:III-3	F2:II-4	F2:III-1	F3:II-1	F3:II-2	F4:III-1	F4:III-2	F4:II-4
Sex of rearing		Male	Male	Male	Female	Male	Male	Male	Male	Male
Age at presentation (yrs)		2.2	1.8	14.0	1.8	0.6	0.08	Newborn	4	2
Diagnosis		ETRS	ETRS	ETRS	ETRS	ETRS	ETRS	ETRS	ETRS	PGD
External genitalia		Micropenis	Micropenis	Micropenis	Micropenis	Micropenis	Micropenis	Micropenis	Micropenis	Micropenis
Gonads		Non-palpable	Non-palpable	Non-palpable	Non-palpable	Non-palpable	Non-palpable	Non-palpable	Non-palpable	Left testis – scrotum
Histologic analysis		Bilateral dysgenetic gonads	L: no gonadal tissue R: dysgenetic gonad	No gonadal tissue	L: no gonadal tissue R: dysgenetic gonad	Bilateral dysgenetic gonads	Bilateral dysgenetic gonads	No gonadal tissue	No gonadal tissue	R: no gonadal tissue L: dysgenetic gonad with IUGN*
Wolff derivatives		Present	Present	Present	Present	Present	Present	Present	Present	Present
Mullerian Derivatives	Tubes	Present	Present	Present	Present	Absent	Present	Present	Present	Absent
	Uterus	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
LH (U/L)		14.5	12	3.5	1.9	0.25	0.17	<0.5	<0.5	26
FSH (U/L)		117	133	87	56	10.9	9.5	NA	9	112
Basal T (ng/dL)		<10	<10	<10	NA	16	<10	38	27	16
T after hCG test (ng/dL)		<10	NA	29	26	18	<10	40	29	NA
Allelic variants		p.Arg308Gln	p.Arg308Gln	p.Arg308Gln	p.Arg308Gln	p.Arg674Trp	p.Arg674Trp	p.Arg674Trp	p.Arg674Trp	p.Arg674Trp
Variants state		Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous

NA- not available; PGD- partial gonadal dysgenesis; IUGN- intratubular undifferentiated germinal neoplasia; * testicular biopsy

L: left; R: right; Conversion factors to SI units: T: testosterone; T ng/dL to nmol/L, multiply by 0.0347

Table 2. Phenotype of 46,XY DSD patients with sporadic gonadal dysgenesis and likely pathogenic *DHX37* allelic variants.

Origin Parameters		Chinese- American	Brazilian					
			F6:II-1	F7:II-1	F8:II-1	F9:II-5	F10:II-1	F11:II-1
Patient		F5:II-1	F6:II-1	F7:II-1	F8:II-1	F9:II-5	F10:II-1	F11:II-1
Social sex		Male	Male to Female	Male to Female	Female	Female	Male to female	Female
Age at presentation (yrs)		0.18	30	4.3	7.7	35	19	3.7
Diagnosis		ETRS	ETRS	ETRS	PGD	Previous gonadectomy	ETRS	PGD
External genitalia		Micropenis	Micropenis	Micropenis	Female	Previous genitoplasty	Micropenis	Atypical
Gonads		Non-palpable	Non-palpable	Non-palpable	Non-palpable	NA	Non-palpable	Non-palpable
Histological analysis		No gonadal tissue	No gonadal tissue	R: no gonadal tissue L: dysgenetic gonad	Bilateral dysgenetic gonads	NA	No gonadal tissue	Bilateral dysgenetic gonads
Wolff derivatives		Present	Present	Present	Present	NA	Present	Present
Mullerian Derivatives	Tubes	Absent	Rudimentary	Present	Absent	NA	Absent	Rudimentary
	Uterus	Absent	Absent	Absent	Absent	Absent	Absent	Absent
LH (U/L)		0.1	10	1	0.1	NA	23	0.1
FSH (U/L)		0.4	40	48.5	4.89	NA	62	0.4
Basal T (ng/dL)		<10	NA	NA	<10	NA	21	<10
T after hCG test (ng/dL)		<10	<10	<10	NA	NA	NA	337
Allelic variants		p.Arg308Gln	p.Arg308Gln	p.Arg151Trp*	p.Arg308Gln	p.Thr304Met	p.Arg674Trp	p.Arg674Trp
Variants state		Heterozygous	Heterozygous	Homozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous

NA: not available; PGD- Partial gonadal dysgenesis; Conversion factors to SI units: T, ng/dL to nmol/L, multiply by 0.0347.

*Variant of uncertain significance




Figure 1. Pedigrees of the eleven families with potential disease-causing *DHX37* variants. Filled symbols represent affected individuals. The affected raised males (46,XY) are indicated by filled squares and the affected raised females (46,XY) are shown by large dark dots within the squares. Symbols with a diagonal line represent deceased individuals. The *DHX37* genotype is shown for the individuals whose DNA sample was available; +/- indicates a heterozygous state; ++ indicates a homozygous state for the variant, and -/- indicates a homozygous state for wild-type allele. NA- DNA not available. The paternity of patient F5:II-1 and F8:II-1 was confirmed.




Figure 2. Identified variants are localized within conserved helicase domains of DHX37. Top: Schematic protein structure of DHX37 showing conserved motifs of the helicase core region, the helicase associated domain (HA2) and the oligonucleotide/oligosaccharide-binding-fold. Middle: Nucleotide-interacting motifs (I, II, and VI), nucleic acid-binding motifs (Ia, Ib, and IV), motif V, which binds nucleic acid and interacts with nucleotides, and motif III, which couples ATP hydrolysis to RNA unwinding (N- N terminus; C- C terminus). Bottom: Amino acids within conserved motifs of the helicase core region. The position of the first and last amino acid within each motif is denoted below left and right, respectively. The position of the allelic variants identified in this study are indicated with vertical arrows and shown in bold in the different species sequence, which the pathogenic variants (p.Arg308Gln, p.Thar304Met and p.Arg674Trp) are located at the Motif Ia and Motif VI.




Figure 3. Immunoexpression patterns of DHX37 at different stages of germ cells differentiation. **A.** Perinuclear halo pattern of protein expression in spermatogonia (original magnification $\times 400$). **B.** Adult seminiferous tubule with germ cells showing perinuclear halo in spermatogonia, progressive paranuclear condensation in spermatocytes and spermatids and absence of DHX37 expression in spermatozoa (original magnification $\times 200$). **C.** Numerous spermatids with punctate perinuclear expression and absence of expression in spermatozoa (original magnification $\times 200$). **D.** Magnified images of spermatogonia with perinuclear halo, spermatocyte with paranuclear condensation and spermatids with punctate perinuclear pattern (original magnification $\times 1000$).




Figure 4. Representation of proposed interactions of DHX37 in the male gonadal development pathway. **A.** Normal testicular development - Interaction of DHX37 with DHX15 and DDX5 helicases leading to normal phosphorylation of AKT1, which interacts with the RHOA/ROCK-MAPK (MAP3K1/AXIN1/MAP3K4/GADD45a) pathways, as well as of ERK1/2 and p38 MAPK protein kinases. ERK1/2 and p38 kinases block the beta-catenin pathway and promote SOX9 stimulation leading to testicular development. **B.** Abnormal testicular development - Changes in DHX37 could interfere with the normal interaction between helicases and cause decreased AKT1 phosphorylation. In this condition, the RHOA/ROCK-MAPK signaling was increased and ERK1/2 and p38 hyperphosphorylation leads to SOX9 repression through beta-catenin/FOXL2 activation, resulting in abnormal testicular development. Factors that promote the action of targets are shown as black arrows. Factors that disrupt the action of targets are shown as broken lines.